⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1676698 | 1.00 | — | — | |
| SCHEMBL1676616 | 0.78 | — | — | |
| SCHEMBL1676617 | 0.78 | — | — | |
| SCHEMBL4611334 | 0.74 | — | — | |
| SCHEMBL3390700 | 0.74 | — | — | |
| SCHEMBL3598285 | 0.74 | — | — | |
| SCHEMBL5579074 | 0.74 | — | — | |
| SCHEMBL9798002 | 0.74 | — | — | |
| SCHEMBL9632102 | 0.74 | — | — | |
| SCHEMBL7670236 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777535-B1 | USEFUL FOR TREATING CONDITIONS WHICH ARISE OR ARE EXACERBATED BY ANGIOGENESIS | ABBOTT LABORATORIES | 2004-08-17 | — | — | US | claimed |
| EP-1242455-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2002-09-25 | — | — | EP | claimed |
| EP-1021200-B1 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | BASF AG (DE) | 2002-02-06 | — | — | EP | claimed |
| US-20010009901-A1 | Antineoplastic peptides | BASF AKTIENGESELLSCHAFT GERMANY | 2001-07-26 | — | — | US | claimed |
| WO-2001038397-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2001-05-31 | — | — | WO | claimed |
| EP-0866800-A2 | ANTINEOPLASTIC PEPTIDES | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-30 | — | — | EP | claimed |
| WO-1997022621-A2 | ANTINEOPLASTIC PEPTIDES | BASF AKTIENGESELLSCHAFT (DE) | 1997-06-26 | — | — | WO | claimed |
| US-8440626-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2013-05-14 | — | — | US | disclosed |
| US-20110098235-A1 | ANTINEOPLASTIC PEPTIDES | ABBOTT GMBH & CO. KG (DE) | 2011-04-28 | — | — | US | disclosed |
| US-7807779-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2010-10-05 | — | — | US | disclosed |
| US-20080234205-A1 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-09-25 | — | — | US | disclosed |
| US-7368528-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-05-06 | — | — | US | disclosed |
| US-20060009392-A1 | Salt with physiologically tolerated acid; resistant to enzymatic degradation; oral administration | ABBOTT GMBH & CO., KG. (US) | 2006-01-12 | — | — | US | disclosed |
| EP-1593686-A1 | Antineoplastic peptides | Abbott GmbH & Co. KG (DE) | 2005-11-09 | — | — | EP | disclosed |
| US-6777535-B1 | USEFUL FOR TREATING CONDITIONS WHICH ARISE OR ARE EXACERBATED BY ANGIOGENESIS | ABBOTT LABORATORIES | 2004-08-17 | — | — | US | disclosed |
| EP-1242455-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20010009901-A1 | Antineoplastic peptides | BASF AKTIENGESELLSCHAFT GERMANY | 2001-07-26 | — | — | US | disclosed |
| WO-2001038397-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2001-05-31 | — | — | WO | disclosed |
| EP-0866800-A2 | ANTINEOPLASTIC PEPTIDES | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-30 | — | — | EP | disclosed |
| WO-1997022621-A2 | ANTINEOPLASTIC PEPTIDES | BASF AKTIENGESELLSCHAFT (DE) | 1997-06-26 | — | — | WO | disclosed |